{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:07:53Z","timestamp":1792782473786,"version":"4.5.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical University of Vienna","id":[{"id":"https:\/\/ror.org\/05n3x4p02","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Magnetic resonance image-guided adaptive brachytherapy (MR-IGABT) is the standard of care for definitive radiochemotherapy in locally advanced cervical cancer, but radiotherapy departments with sufficient case volume and unrestricted access to MRI capacity remain limited. This study evaluated the feasibility and outcomes of a\u00a0nationwide Austrian model combining decentralized external-beam radiotherapy (EBRT) with centralized MR-IGABT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included patients with FIGO IB\u2013IVA cervical cancer treated between 2018 and 2022 who received EBRT\u202f\u00b1\u2009concomitant chemotherapy at external Austrian institutions and were subsequently referred to the Medical University of Vienna for brachytherapy. All patients received four fractions of MR-IGABT with MRI-based target delineation according to GEC-ESTRO recommendations. Primary endpoints were local control (LC) and overall survival (OS). Secondary endpoints included pelvic lymph node control (PLNC), recurrence-free survival (RFS), and grade \u2265\u202f3 morbidity requiring medical intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eighty-nine patients from nine institutions were analyzed. Median age was 52\u00a0years; 54% had T2b disease and 60% nodal involvement, including 17% paraaortic nodes. Median overall treatment time was 50\u00a0days, with a\u00a0median 6.5-day interval between EBRT and brachytherapy. Combined intracavitary\/interstitial brachytherapy was used in 87%, with a\u00a0median of six needles. The median CTV\n                      <jats:sub>HR<\/jats:sub>\n                      D90 was 91\u202fGy EQD2. After a\u00a0median follow-up of 36\u00a0months, the estimated 3\u2011year OS was 74%, LC 95%, PLNC 95%, and RFS 65%. Recurrences were predominantly distant. Grade \u2265\u202f3 morbidity occurred in 26.1%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Centralized MR-IGABT within a\u00a0nationwide referral network is feasible and enables guideline-conform, high-quality cervical cancer treatment in a\u00a0real-world setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00066-026-02607-z","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:36:20Z","timestamp":1790310980000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Centralization of MR image-guided adaptive brachytherapy for cervical cancer in Austria: feasibility and outcomes"],"prefix":"10.1007","author":[{"given":"J.","family":"Knoth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Ramadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. M.","family":"Weis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Kurzweil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Celedin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Komina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Salinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"B\u00f6swarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Skorbier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Buchegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kartal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Flatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Metz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Widder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Reim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Eder-Nesvacil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kirisits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Raunik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Georg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Geinitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sturdza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. P","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"issue":"1","key":"2607_CR1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.radonc.2005.11.014","volume":"78","author":"R P\u00f6tter","year":"2006","unstructured":"P\u00f6tter\u00a0R, Haie-Meder\u00a0C, Van Limbergen\u00a0E, Barillot\u00a0I, De Brabandere\u00a0M, Dimopoulos\u00a0J et\u00a0al (2006) Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Clin Transl Radiat Oncol 78(1):67\u201377. https:\/\/doi.org\/10.1016\/j.radonc.2005.11.014 (PubMed PMID: 16403584)","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"issue":"3","key":"2607_CR2","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.radonc.2004.12.015","volume":"74","author":"C Haie-Meder","year":"2005","unstructured":"Haie-Meder\u00a0C, P\u00f6tter\u00a0R, Van Limbergen\u00a0E, Briot\u00a0E, De Brabandere\u00a0M, Dimopoulos\u00a0J et\u00a0al (2005) Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Clin Transl Radiat Oncol 74(3):235\u2013245. https:\/\/doi.org\/10.1016\/j.radonc.2004.12.015 (PubMed PMID: 15763303)","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"issue":"4","key":"2607_CR3","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/S1470-2045(20)30753-1","volume":"22","author":"R P\u00f6tter","year":"2021","unstructured":"P\u00f6tter\u00a0R, Tanderup\u00a0K, Schmid\u00a0MP, J\u00fcrgenliemk-Schulz\u00a0I, Haie-Meder\u00a0C, Fokdal\u00a0LU et\u00a0al (2021) MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. Lancet Oncol 22(4):538\u2013547. https:\/\/doi.org\/10.1016\/S1470-2045(20)30753-1 (PubMed PMID: 33794207)","journal-title":"Lancet Oncol"},{"key":"2607_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.109682","volume":"184","author":"D Cibula","year":"2023","unstructured":"Cibula\u00a0D, Raspollini\u00a0R, Planchamp\u00a0F, Centeno\u00a0C, Chargari\u00a0C, Felix\u00a0A et\u00a0al (2023) ESGO\/ESTRO\/ESP Guidelines for the management of patients with cervical cancer - Update 2023. Clin Transl Radiat Oncol 184:109682. https:\/\/doi.org\/10.1016\/j.radonc.2023.109682 (PubMed PMID: 37336614)","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"issue":"1","key":"2607_CR5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ygyno.2021.10.073","volume":"164","author":"C Chargari","year":"2022","unstructured":"Chargari\u00a0C, Arbyn\u00a0M, Leary\u00a0A, Abu-Rustum\u00a0NR, Basu\u00a0P, Bray\u00a0F et\u00a0al (2022) Increasing global accessibility to high-level treatments for cervical cancers. Gynecol Oncol 164(1):231\u2013241. https:\/\/doi.org\/10.1016\/j.ygyno.2021.10.073 (PubMed PMID: 34716024; PubMed Central PMCID: PMC9496636)","journal-title":"Gynecol Oncol"},{"key":"2607_CR6","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.gore.2017.08.004","volume":"22","author":"AW LaVigne","year":"2017","unstructured":"LaVigne\u00a0AW, Triedman\u00a0SA, Randall\u00a0TC, Trimble\u00a0EL, Viswanathan AN (2017) Cervical cancer in low and middle income countries: Addressing barriers to radiotherapy delivery. Gynecol Oncol Rep 22:16\u201320. https:\/\/doi.org\/10.1016\/j.gore.2017.08.004 (PubMed PMID: 28948205; PubMed Central PMCID: PMC5602511)","journal-title":"Gynecol Oncol Rep"},{"key":"2607_CR7","unstructured":"P\u00f6tter R. EMBRACE II study protocol [Internet]. Available from: https:\/\/www.embracestudy.dk\/UserUpload\/PublicDocuments\/EMBRACE%20II%20Protocol.pdf"},{"key":"2607_CR8","doi-asserted-by":"crossref","unstructured":"Eder-Nesvacil et\u00a0al. Change of practice in MR-guided adaptive brachytherapy for cervical cancer by a\u00a0multiparametric dose prescription protocol: From EMBRACEI to EMBRACEII, ESTRO 2025 - Abstract Book S265\u20136 [Internet]. [cited 2026 Apr\u00a015]. Available from: https:\/\/user-swndwmf.cld.bz\/ESTRO-2025-Abstract-Book","DOI":"10.1016\/S0167-8140(25)01751-7"},{"issue":"12","key":"2607_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14122935","volume":"14","author":"R Bentahila","year":"2022","unstructured":"Bentahila\u00a0R, Rassy\u00a0E, Achkar\u00a0S, Sacino\u00a0F, Bougas\u00a0S, Vallard\u00a0A et\u00a0al (2022) Providing Patients with Locally Advanced Cervical Cancer Access to Brachytherapy: Experience from a Referral Network for Women Treated in Overseas France. Cancers 14(12):2935. https:\/\/doi.org\/10.3390\/cancers14122935 (PubMed PMID: 35740601; PubMed Central PMCID: PMC9221527)","journal-title":"Cancers"},{"issue":"3","key":"2607_CR10","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.radonc.2016.05.014","volume":"120","author":"K Tanderup","year":"2016","unstructured":"Tanderup\u00a0K, Fokdal\u00a0LU, Sturdza\u00a0A, Haie-Meder\u00a0C, Mazeron\u00a0R, van Limbergen\u00a0E et\u00a0al (2016) Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer. Clin Transl Radiat Oncol 120(3):441\u2013446. https:\/\/doi.org\/10.1016\/j.radonc.2016.05.014 (PubMed PMID: 27350396)","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"issue":"49","key":"2607_CR11","doi-asserted-by":"publisher","first-page":"85203","DOI":"10.18632\/oncotarget.19617","volume":"8","author":"SM Lin","year":"2017","unstructured":"Lin\u00a0SM, Ku\u00a0HY, Chang\u00a0TC, Liu\u00a0TW, Hong\u00a0JH (2017) The prognostic impact of overall treatment time on disease outcome in uterine cervical cancer patients treated primarily with concomitant chemoradiotherapy: a nationwide Taiwanese cohort study. Oncotarget 8(49):85203\u201385213. https:\/\/doi.org\/10.18632\/oncotarget.19617 (PubMed PMID: 29156713; PubMed Central PMCID: PMC5689603)","journal-title":"Oncotarget"},{"issue":"1","key":"2607_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.brachy.2011.07.002","volume":"11","author":"AN Viswanathan","year":"2012","unstructured":"Viswanathan\u00a0AN, Beriwal\u00a0S, De Los Santos\u00a0J, Demanes\u00a0DJ, Gaffney\u00a0D, Hansen\u00a0J et\u00a0al (2012) The American Brachytherapy Society Treatment Recommendations for Locally Advanced Carcinoma of the Cervix Part II: High Dose-Rate Brachytherapy. Brachytherapy 11(1):47\u201352. https:\/\/doi.org\/10.1016\/j.brachy.2011.07.002 (PubMed PMID: 22265437; PubMed Central PMCID: PMC3489267)","journal-title":"Brachytherapy"},{"key":"2607_CR13","doi-asserted-by":"crossref","unstructured":"P\u00f6tter R (2025) EMBRACE II - a\u00a0multicenter prospective interventional cohort study on IGRT-IMRT+cisplatin+MR-IGABT in locally advanced cervix cancer: overall results ESTRO 2025 - Abstract Book S837\u201340. https:\/\/user-swndwmf.cld.bz\/ESTRO-2025-Abstract-Book. Accessed 15 Apr 2026 (Internet)","DOI":"10.1016\/S0167-8140(25)01194-6"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-026-02607-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-026-02607-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-026-02607-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:36:31Z","timestamp":1790310991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-026-02607-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":13,"alternative-id":["2607"],"URL":"https:\/\/doi.org\/10.1007\/s00066-026-02607-z","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"21 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Medical University of Vienna (EK Nr. 1489\/2023).","order":1,"name":"Ethics","label":"Ethical standards","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J.\u00a0Knoth, H.\u00a0Ramadan, E.M.\u00a0Weis, G.\u00a0Kurzweil, B.\u00a0Celedin, O.\u00a0Komina, J.\u00a0Salinger, J.\u00a0B\u00f6swarth, S.\u00a0Skorbier, M.\u00a0Buchegger, S.\u00a0Kartal, S.\u00a0Flatz, J.\u00a0Frey, O.\u00a0Gomez, M.\u00a0Kopp, M.\u00a0Metz, A.\u00a0de Vries, T.\u00a0Brunner, J.\u00a0Widder, A.\u00a0Reim, N.\u00a0Eder-Nesvacil, C.\u00a0Kirisits, W.\u00a0Raunik, P.\u00a0Georg, H.\u00a0Geinitz, A.\u00a0Sturdza, and M.P.\u00a0Schmid declare that they have no competing interests. The Department of Radiation Oncology at the Medical University of Vienna has institutional research contracts with RaySearch Laboratories (Sweden), ELEKTA Ltd. (Sweden), Philips Austria GmbH (Austria), and Brainlab SE (Germany), which are not related to this study.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}